A woman with a history of depression was treated with an injection of leuprolide, allegedly causing her to attempt suicide 11 day later.
A 27-year-old New York woman with a history of depression was diagnosed with endometriosis in 2003. Her gynecologist treated her with an injection of leuprolide (Lupron). Five days later the patient called the doctor's office and reported she was suffering depression and she was seen the following day. Eleven days later she unsucessfully attempted suicide, then underwent 3 days of inpatient psychiatric evaluation and was diagnosed with bipolar disorder. She was then treated as an outpatient.
The woman sued the gynecologist, alleging that her depression and attempted suicide were caused by the leuprolide, and that it was negligent to give it and not disclose the risk of depression. She claimed she was unable to endure the company of people and so is unable to work.
The gynecologist claimed depression is a rare side effect of Lupron and it did not need to be disclosed and the patient's depression has subsided. She argued the depression was not from the drug. A defense verdict was returned.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More